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List abbreviations in the order cited 
ABL abetalipoproteinemia 
MTTP microsomal triglyceride transfer protein large subunit gene 
MTP microsomal triglyceride transfer protein large subunit 
PDI protein disulfide isomerase  
P4HB prolyl 4-hydroxylase, beta polypeptide 
ApoB apolipoprotein B  
MCT medium chain triglyceride 
PCSK9 proprotein convertase subtilisin/kexin type 9 
ANGPTL3 angiopoietin-like 3 
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Abstract  
Abetalipoproteinemia (ABL) is an inherited disease characterized by the 
defective assembly and secretion of apolipoprotein B-containing lipoproteins caused 
by mutations in the microsomal triglyceride transfer protein large subunit (MTP) gene 
(MTTP). We report here a female patient with an unusual clinical and biochemical 
ABL phenotype. She presented with severe liver injury, low levels of LDL-cholesterol, 
subnormal levels of vitamin E, but only mild fat malabsorption and no retinitis 
pigmentosa or acanthocytosis. Our objective was to search for MTTP mutations and 
to determine the relationship between the genotype and this particular phenotype.  
The subject exhibited compound heterozygosity for two novel MTTP 
mutations: one missense mutation (p.Leu435His) and an intronic deletion (c.619-
5_619-2del). COS-1 cells expressing the missense mutant protein exhibited 
negligible levels of MTP activity. In contrast, the minigene splicing reporter assay 
showed an incomplete splicing defect of the intronic deletion with 26% of the normal 
splicing being maintained in the transfected HeLa cells. 
The small amount of MTP activity resulting from the residual normal splicing in 
the patient explains the atypical phenotype observed. Our investigation provides an 
example of a functional analysis of unclassified variations, which is an absolute 
necessity for the molecular diagnosis of atypical ABL cases. 
Supplementary key words: dyslipidemias, familial hypocholesterolemia, 
chylomicrons, lipoprotein/assembly, hepatosteatosis, genetics, gene expression, 
genotype-phenotype correlation, functional analysis, splicing 
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Abetalipoproteinemia (ABL; OMIM#200100) is an autosomal recessive 
hypocholesterolemia usually detected during infancy due to failure to thrive, severe 
diarrhoea and a lipid malabsorption syndrome. Sixty years ago, Bassen and 
Kornzweig described this disease for the first time (1) and forty years later, the role of 
MTP (microsomal triglyceride transfer protein large subunit) was discovered (2-5). 
MTP forms a heterodimer with protein disulfide isomerase (PDI) also named prolyl 4-
hydroxylase beta polypeptide (P4HB) which is responsible of the assembly of 
apolipoprotein B (ApoB) containing lipoproteins in the liver and the intestine. 
Following the discovery of the first mutations, many mutations have been identified in 
the microsomal triglyceride transfer protein large subunit gene (MTTP) in patients (3-
6). The identification of mutations in the MTTP gene in DNA from patients is 
important for establishing the diagnosis of ABL in the context of two other hereditary 
hypocholesterolemias (homozygous familial hypobetalipoproteinemia OMIM#107730 
and Anderson’s disease/Chylomicron retention disease, OMIM#246700) which are 
due to mutations in the APOB and SAR1B genes, respectively.  
 To date, mutations in the MTTP gene have been established in about 50 
cases of ABL (7-12). In some instances, the prediction of altered MTP function is 
readily made on the basis of premature stop codons, mutations in canonical splice 
sites or frameshift mutations. In other cases, the functional consequences have been 
difficult to predict (13-15), even if the mutations co-segregate with clinical phenotype. 
The measurement of MTP activity (2, 3, 6, 11, 13, 16, 17) and the consequence of 
intronic mutations (9, 11) have been studied in only a few cases due to the necessity 
of additional intestinal or hepatic biopsies. 
 ABL patients are usually diagnosed during infancy and they exhibit marked 
lipid malabsorption, very low levels of cholesterol and triglycerides, the absence of 
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ApoB in the plasma, the absence of chylomicrons after fat loading, and essential fatty 
acid and fat-soluble vitamin deficiencies (particularly vitamin E). Hepatic steatosis 
has not been reported uniformly (although it is frequent), and hepatic fibrosis or 
cirrhosis has been reported in a few cases (18, 19). We report here an atypical case 
of ABL presenting in childhood with severe liver injury, hypocholesterolemia 
associated with a low (but not absent) levels of plasma ApoB and a subnormal level 
of plasma vitamin E. Furthermore, the patient exhibited normal development into 
adulthood. ABL was suspected because of the presence, at the ultrastructural level, 
of large amounts of free lipid droplets accumulated in the cytoplasm of enterocytes 
and hepatocytes in intestinal and liver biopsies. 
The patient was found to be compound heterozygous for two novel mutations 
in the MTTP gene, one intronic (c.619-5_619-2 del, from her mother) and the other a 
missense mutation (p.Leu435His, from her father). The possible functional impact of 
these two mutations was not readily apparent. Since no additional biopsy material 
was available from the patient, two different assays were established. COS-1 cells 
were transfected with wild type and several mutant MTTP cDNAs in order to evaluate 
the impact of the missense mutation on MTP activity and HeLa cells were transfected 
with wild-type and mutant minigenes to evaluate possible defects in splicing.  
 
Material and methods 
Patient (diagnosis and follow-up) 
A 4 year-old girl was referred for an anicteric chronic hepatitis fortuitously 
discovered 10 months previously. The level of blood transaminases were consistently 
elevated and ranged from 5 to 7 times the normal values associated with 
bilirubinemia in the absence of inflammation or hepatic insufficiency. Upon clinical 
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examination, the liver was moderately enlarged and firm, but there was no other sign 
of chronic liver disease. The patient’s growth was normal. The patient’s parents 
altered her diet to avoid fatty foods following episodes of diarrhoea in the first months 
of life. The levels of total cholesterol and ApoB in the plasma were found to be low, 
whereas the level of triglyceride was normal (Table1). The parents were not related 
and they had normal levels of blood lipids.  
 A perendoscopic jejunal biopsy, performed as previously described (20), 
showed a white mucosa. Electron microscopic examination of the biopsy showed 
enterocytes with many small or very large free lipid droplets scatterred throughout the 
cytoplasm (Figure 1a, 1b). Examination by ultrasound showed that the liver was 
moderately enlarged and slightly hyper-echogenic. A percutaneous liver biopsy 
showed extensive fibrosis (scored F3 according to the METAVIR scoring system 
(21)) which was associated with a massive micro- and macro-vesicular steatosis. 
Large amounts of free lipid droplets were observed in the cytoplasm by electron 
microscopy (Figure 1c). Abetalipoproteinemia was suspected although retinitis 
pigmentosa and acanthocytosis were absent and the blood vitamin E level was only 
slightly decreased. The fecal fat content, measured over a 3 day period, was also 
normal (mean 2.8 g/24h, normal < 3g/24h). However, when the child consumed a 
normal fat diet (33% fat), diarrhoea occurred and steatorrhoea was 24 g/day. After an 
oral fat load (Table1), the level of serum triglycerides increased slightly and a small 
amount of chylomicrons appeared in the plasma, suggesting that some intestinal lipid 
absorption occurs accompanied by low levels of intestinal lipoprotein secretion. 
 A diet limited in saturated fatty acids (22% of total energy) and enriched with 
medium chain triglycerides (MCT) was begun and resulted in the elimination of 
diarrhoea, progressive improvement in liver function (transaminases 2 to 4 X normal 
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at the age of 7 years, 2 to 3 X normal at 14 years, normal values at 18 years of age), 
the normalization of the levels of essential fatty acids and fat soluble vitamins, and 
normal growth and puberty. At the age of 14 years, the patient no longer adhered to 
the MCT diet and 36% of total energy intake was composed of fat. Hepatitis recurred 
(transaminases increased to 150 to 200 X normal) but resolved when the MCT diet 
was re-instituted.  
 The patient is now 22 years of age and is in good health. Fat soluble vitamins 
are in the normal range without any supplementation. The levels of transaminases 
are < 1.5 X normal and hepatic steatosis persists (16% of hepatic parenchyma as 
determined by magnetic resonance imaging). There are no neurological, 
ophthalmological or retinal abnormalities. 
Blood samples, intestinal and liver biopsies were obtained from the patient 
using the procedures and the experimental methods approved by INSERM (RBM 
0256) and by a bioethics committee (Comité Consultatif de Protection des Personnes 
dans la Recherche Biomédicale de Paris Bichat-Claude Bernard, Paris, France, 
CCPPRB Bichat-C. Bernard-2003/05). Informed, written consent was obtained from 
the patient’s parents. 
 
Mutation analysis 
Following the extraction of genomic DNA from the blood (Nucleon Bac3, GE 
Healthcare®, Chalfont St. Giles, UK, http://www.gehealthcare.com), each of the 
coding exons, and the flanking intronic junctions, of the MTTP, APOB, proprotein 
convertase subtilisin/kexin type 9 (PCSK9) and angiopoietin-like 3 (ANGPTL3) genes 
was amplified by PCR. The amplicons were sequenced directly with the BigDye® 
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Terminator v3.1Cycle Sequencing Kit on an ABI PRISM 3130 or 3730 DNA 
sequencer (Applied Biosystems, Foster City, USA, www.appliedbiosystems.com).  
 
In Silico Analysis 
Analysis of the mutations was performed with Alamut v2.0 (Interactive 
Software), Polyphen (http://genetics.bwh.harvard.edu/pph/) and SIFT 
(http://sift.jcvi.org/www/SIFT_aligned_seqs_submit.html). Several algorithms were 
used for computational scoring of 3’ splice site based on different concepts using 
default parameter settings (Neural Network Splice Prediction (NNSplice) (22), 
MaxEntScan (23), Splice site Finder Like, GeneSplicer (24), Human Splicing Finder 
(HSF) (25)). 
 
Protein expression  
To evaluate the p.Leu435His protein expression, two assays were performed. 
First, to measure wild type and mutant MTP activities, we transfected COS-1 cells 
with the MTTP and P4HB cDNA. Second, to compare the production of wild type and 
p.Leu435His, we transfected COS-1 cells with wild type and mutated MTTP cDNA C-
ter tagged with GFP. 
 
MTP activity 
A 2699 bp fragment containing the entire MTTP coding sequence, extending 
from c.-5 to c.*9 (NM_000253.2) and a 1582 bp fragment containing the entire P4HB 
coding sequence (from c.-14 to c.1527, NM_000918.3) were obtained by RT-PCR 
from 1µg of human liver total RNA (Cat.No.636531, Clontech, Mountain View, U.S.A, 
www.clontech.com) with the Transcriptor High Fidelity cDNA Synthesis Sample Kit 
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(Cat.No.05081963001 Roche Applied Science, Indianapolis, USA, www.roche-
applied-science.com). 
The MTTP cDNA was inserted, with the In-Fusion Advantage PCR Cloning Kit 
(Cat.No.639616, Clontech, Mountain View, U.S.A, www.clontech.com), into the Kpn I 
site of the pBudCE4.1 expression vector (Cat.No.V532-20 Invitrogen, Carlsbad, 
U.S.A, www.invitrogen.com) downstream of the human elongation factor 1-subunit 
promoter. The P4HB cDNA was inserted into the Hind III site of the same vector, 
downstream of the human cytomegalovirus immediate-early promoter, allowing the 
production of the two proteins from the same plasmid. 
The p.Leu435His (c.1304T>A), p.Leu435Glu (c.1303_1305delinsGAA), 
p.Leu435Val (c.1303C>G) and p.Cys194Stop (c.582C>A) mutants were constructed 
from the wild type sequence with the QuickChange II XL Site-Directed Mutagenesis 
Kit (Cat.No.200521 Stratagene, Agilent Technologies, Cedar Creek, USA, 
www.agilent.com) according to the manufacturer’s instructions. 
Transient expression of MTP and P4HB in COS-1 cells (Cat. No. CRL-1650 
ATCC) was carried out by transfecting 6 µg of plasmid per T25 flask in the presence 
of 9 µL of FuGENE® HD (Cat.No.4709691001 Roche Applied Science, Indianapolis, 
USA, www.roche-applied-science.com), according to the manufacturer’s instructions.  
COS-1 cells were harvested by trypsinization 48 hours post-transfection and 
disrupted by sonication. Triglyceride transfer from donor to acceptor vesicles was 
measured by a fluorescent-labelled method using a commercial kit (R100 MTP 
activity, Chylos Inc, USA, www.chylos.com) according to the manufacturer’s 
instructions and previously described fluorescent methods (26-28). The results are 
expressed as % transfer/mg total proteins/h. The method was evaluated with 
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intestinal and hepatic biopsies and the MTP activities were in agreement with 
previous published results (data not shown). 
Visualisation of MTP in transfected cells 
A fragment containing the MTTP cDNA, extending from c.1 to c.2682 
(NM_000253.2) of each sequence (wild type, p.Cys194Stop, p.Leu435His) was 
amplified from the previously obtained pBudCE4.1 vector. The MTTP cDNA was 
inserted, with the In-Fusion Advantage PCR Cloning Kit into the KpnI site of 
pAcGFP1-N1 expression vector (Cat.No.632469 Clontech, Mountain View, U.S.A, 
www.clontech.com) between the immediate early promoter of the CMV (PCMV IE) 
and the AcGFP1 cDNA allowing the fusion of the MTP and the GFP proteins. COS-1 
cells were electroporated with 0.5 µg of MTP-AcGFP1 plasmid per 80 000 cells 
(MicroPorator, DigitalBio Technology and Neon Transfection System 10µL Kit, 
Cat.No. MPK1096, Invitrogen Carlsbad, U.S.A, www.invitrogen.com) according to the 
manufacturer’s instructions (1050V, 30ms, 2 pulses). Intracellular fluorescence was 
observed with a Nikon Eclipse TE 2000-U microscope 48h after transfection. 
 
Minigene Splicing Reporter Assay 
A 371 bp MTTP fragment (the last 147 bases of intron 5, 140 bp of exon 6, 
and the first 84 bases of intron 6) was amplified from the patient’s DNA and inserted 
(In-Fusion Advantage PCR Cloning Kit) into the Nde I restriction site of the pTB 
minigene vector (29). The transfection of normal and mutant minigenes into HeLa 
cells and RT-PCR procedures were as previously described (30). 
The fluorescence of the ethidium bromide bands obtained following gel 
electrophoresis of RT–PCR products was integrated under unsaturated conditions 
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(Quantity One® 1-D Analysis Software Cat. No170-9600, BIO-RAD, www.bio-
rad.com) to derive band intensities. 
 
Metabolic labelling of intestinal biopsies 
Intestinal biopsies from normal individuals and from the patient were placed 
into organ culture and metabolically labelled with [35S] methionine as described 
previously (31). After homogenization and solubilization, the labelled intestinal biopsy 
extracts and the corresponding media were immunoprecipitated with polyclonal 
antibodies against Apo B (Rabbit polyclonal antibodies to Apo B were the gifts of Dr 
A. Mazur of Institut National de la Recherche Agronomique, Champanelle, France) 
and MTP (31). For semi-quantitative analysis, densitometric analysis was performed 
using the PC version of NIH Image software (Scion Image) after photography with a 
computer-assisted camera (GS-800 Calibrated Densitometer, BIO-RAD). The values 
were normalized with respect to the amount of TCA precipitable incorporated 
material in the biopsies.  
 
 
Results 
Identification of mutations 
Sequencing was performed on the genomic DNA of the patient and her 
parents. Two novel variants of the MTTP gene were identified in the patient. The first, 
inherited from her father, is a change from T to A at position c.1304 in exon 10 
(Supplemental Data, Figure 1A) (Nucleotide numbering starts at A of the ATG 
initiating codon and exon 1 is the first coding exon) which changes the amino acid 
Leu 435 to a His. The second, inherited from her mother, is a 4 bp deletion in intron 
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5: c.619-5_619-2 del (Supplemental Data, Figure 1B). This deletion of a repeated 
motif (TTTA) is upstream the acceptor site. These mutations were found neither in 
our panel of 100 normal alleles from unrelated subjects nor in the 1000 genomes 
database (32). 
The patient is also heterozygous for a well described polymorphism 
p.Gln95His inherited from her father. The frequency of this allele is between 5.4 and 
6% in a healthy adult Caucasian population (England) and in a sample of 270 
unrelated French Canadian men (6, 33) and 6.2% in a cohort of abetalipoproteinemia 
(6).  
The patient had no mutation in the APOB, PCSK9 or ANGTL3 genes.  
 
Analysis of  c.1304 T>A, p.Leu435His: 
The missense mutation (p.Leu435His) is located in exon 10 and affects a 
highly conserved residue in the middle -helical domain of MTP. The substitution 
changes a hydrophobic to a hydrophilic, basic residue (Grantham distance: 99 [0-
215]). This missense mutation is predicted by Polyphen to be “probably damaging” 
with a score of 0.99 and by SIFT to “affect protein function”.  
To determine whether the p.Leu435His missense mutation produces a protein 
that is functional or not, we expressed, in COS-1 cells, the wild type MTP as well as 
the p.Leu435His and several other mutants (p.Leu435Glu, p.Leu435Val and 
p.Cys194Stop). These different mutations were tested in COS-1 cells to evaluate the 
sensitivity and specificity of our MTP activity assay: p.Leu435Glu is expected to be 
as severe as p.Leu435His as it changes the hydrophobic Leu to a hydrophilic acidic 
Glu, whereas p.Leu435Val is expected to be a mild change (Leu and Val are both 
hydrophobic and closely related amino acids). The introduction of a premature stop 
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codon at the position p.Cys194 is expected to lead to the complete abolition of MTP 
activity since the ApoB and PDI binding sites are absent from the mutant. Further, 
the homozygous p.Cys194Stop mutation has been reported in an ABL patient (8). 
As shown in Figure 2, cells expressing p.Leu435His (the patient’s mutation), 
p.Cys194Stop, or p.Leu435Glu have negligible levels of MTP activity (0.30 to 1.9% 
TG transfer/30µg protein/h) as compared to cells expressing p.Leu435Val or the wild 
type protein (24.15 to 27.25 % TG transfer/30µg protein/h respectively). The activity 
of the p.Leu435His MTP is not significantly different from the p.Cys194Stop truncated 
protein and, thus, must be considered as having a negligible MTP activity as 
compared to the wild-type protein. RT-PCR of the MTTP and P4HB transcripts in 
transfected COS-1 cells shows that the level of expression from each vector is 
comparable for the wild type and the different mutant transfected cDNA 
(Supplemental Data, Figure 2A and 2B). Fluorescent tagged MTP showed an 
identical cellular distribution (Supplemental Data, Figure 2C).The p.Leu435His 
mutant, therefore, is functionally defective. 
 
Analysis of c.619-5_619-2del: 
Splicing predictions 
All the algorithms predicted an effect on splicing with a decrease in the score 
for the acceptor site of intron 5 ranging from -10% for SSF-like to a complete 
abolition for GeneSplicer, (-44% for MaxEnt Scan, -38.9% for NNSplice, -79% for 
HSF). Given that all the algorithms predicted an effect on splicing, experimental 
analysis of splicing was performed. HeLa cells transfected with wild type or mutant 
minigenes were analyzed (size and sequence) by RT-PCR to determine the 
presence of abnormal transcript processing of the mutant. 
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Minigene splicing reporter assay 
Transfection of the wild type minigene into HeLa cells produced, as expected, 
a 386 bp RT-PCR fragment (Figure 3, lanes 1, 2 3). In contrast, transfection of the 
mutant c.619-5_619-2del minigene produced 2 different RT-PCR fragments: a small 
amount of a fragment of normal size (386bp) and a large amount of a 248 bp product 
(lanes 4, 5, 6). The sequence of the 386 bp PCR product includes exon 6 of MTTP 
whereas exon 6 is skipped in the 248 bp product (Supplemental Data, Figure 3). This 
result shows that c.619-5_619-2del mutation produces two differently spliced 
transcripts: one containing exon 6 and the other without exon 6. Exon 6 skipping 
would result in a protein containing the first 206 MTP amino acids but followed by 26 
aberrant amino acids and a premature stop codon. In vivo, this mutant mRNA might 
be targeted for nonsense mediated decay and degraded. By densitometry of the 
agarose gel, the amount of normal splicing for the mutant minigene is estimated to be 
26% of that of the wild type (Figure 3). These data indicate that the c.619-5_619-2del 
is a splice site mutation which can lead to the skipping of exon 6. However, the effect 
of this mutation on splicing is not complete and about 26% of the transcript is 
correctly spliced. 
 
Biosynthesis of ApoB and MTP in intestinal organ culture 
Immunoprecipitation with polyclonal antibodies to ApoB of the medium and the 
total homogenate of the organ culture of intestinal biopsies from the patient showed 
the synthesis of an ApoB48 identical in size to that of normal control subjects (Figure 
4). Analysis by densitometry with correction for the amount of incorporated TCA 
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precipitable incorporated radioactivity showed that there is an intracellular retention 
of ApoB48 (1.6 fold more) and a decreased ApoB48 secretion (1.3 fold less). 
Immunoprecipitation with polyclonal antibodies to MTP of the total 
homogenate of the organ culture of intestinal biopsies from the patient showed the 
synthesis of a large subunit of identical in size to that of normal control subjects. 
However, by densitometric analysis, there was 2.49 fold less MTP synthesized in the 
patient’s biopsy as compared to that of the normal control subject after correction. A 
protein band corresponding to the molecular mass of PDI co-immunoprecipitated with 
the MTP in the patient as was observed for the normal control subject (identical in 
amount as compared to that of the normal subject after correction). 
 
Discussion 
In this paper, we describe two new mutations in the MTTP gene: p.Leu435His 
and a 4 bp deletion in intron 5: c.619-5_619-2 del. Since the impact of these 
mutations was unclear and the phenotype was atypical, cellular functional tests were 
used to further understand this new case of ABL.  
The diagnosis of ABL is made readily if the following criteria are present during 
the first months of life: severe diarrhoea, failure to thrive, undetectable vitamin E, 
severe hypocholesterolemia and hypotriglyceridemia with undetectable amounts of 
plasma ApoB, and the absence, post-prandially, of chylomicrons in the serum. Our 
patient presented with a mild phenotype and lacked the major criteria for the 
diagnosis of ABL. Surprisingly, the patient was referred only for anicteric chronic 
hepatitis with major liver steatosis at 4 years of age. The other causes of 
hypobetalipoproteinemias were ruled out because of the patient’s lipids profile and 
normal lipid values of the parents (34-40). Furthermore, no mutation was found in the 
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PCSK9, ANGPTL3, APOB genes. The diagnosis of ABL was finally suspected 
because of hypocholesterolemia and the typical aspect of intestinal and liver biopsies 
suggesting a defect in the assembly of ApoB-containing lipoproteins.  
Seven atypical cases of ABL have been reported (13-15, 19, 41, 42). For five 
of these patients (Table 2) a molecular diagnosis of the mutation in MTTP was 
established. However, a functional assay of the mutation was performed in only one 
case (13). Two of the cases (cases 1 and 2 in Table 2) are very surprising. Both the 
patients have deleterious mutations, however, the first patient exhibits a mild 
phenotype (42) and the other is almost asymptomatic (13). Two other patients (cases 
4 and 5 in Table 2) are homozygous for the same p.Ser590Ile mutation (14, 15). 
Unfortunately the functional impact of this mutation has not been established. Only 
the third case (19) (Table 2) resembles our case, clinically and biologically. This 
patient exhibits compound heterozygosity for a splice-site and a missense mutation, 
along with liver dysfunction and slightly decreased level of vitamin E. 
The p.Leu435His mutation affects an amino-acid in helix 8 of the predicted -
helical domain of MTP (43). Although this helix is not included in the major binding 
site for PDI and ApoB (43-45), the MTP activity of the mutant protein is very low and 
similar to that of “severe” mutations. The p.Leu435His mutation leads to a non-
functional protein probably by affecting the MTP folding. Misfolded MTP may be 
targeted for degradation in the intestine or the liver; however, this recognition of 
misfolded proteins cannot be observed in heterologous expression systems 
(transfected COS-1 cells). 
The c.619-5_619-2del is probably responsible for the mild phenotype as it 
produces two transcripts. One is normal-sized and contains exon 6 of the MTTP. The 
other transcript is aberrantly spliced and lacks exon 6. The phenotype may result 
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from the correctly spliced RNA which is able to produce an active MTP. Although 
there may be some variability in the amounts of correctly spliced RNA between HeLa 
cells and the liver or the intestine, the marked effect of the intronic deletion observed 
in HeLa cells most likely reflects what might be expected in other cell types. A 
possible molecular mechanism for this splicing anomaly, predicted by the in silico 
analysis, is the shortening of the polypyrimidine tract by the deletion of one TTTA 
repeat. Short polypyrimidine tracts have been showed to be associated with variable 
levels of correctly spliced transcripts in the CFTR gene (46) thus providing evidence 
for incomplete penetrance of some splicing mutations in disease.  
In our patient, the lipid transfer activity of the MTP produced from the normally 
spliced transcript may be sufficient to allow the assembly and secretion of a relatively 
limited amount of ApoB-containing lipoproteins by liver and intestine and could 
explain the presence of the lipid absorption (as shown by metabolic labelling 
biosynthesis data) observed in the intestine of the patient. Both the intracellular 
accumulation and the decreased secretion of ApoB48 from the intestine are 
consistent with a partial defect in the assembly of ApoB which leads to a partial 
defect in secretion of ApoB48 (unusual in ABL). In addition, the data also suggest 
that a low amount of intestinal MTP was present with a normal molecular weight and 
with an intact PDI binding domain. Finally, the presence of a limited amount of fat 
absorption and lipoprotein secretion could explain the normal level of vitamin E and 
the normal development with only a low fat diet as treatment. However, the residual 
MTP activity is not sufficient to prevent the accumulation of lipids in the enterocytes 
and the hepatocytes.  
In conclusion, our study of this atypical case of abetalipoproteinemia shows 
that the combination of molecular diagnosis and functional analysis resulted in a 
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definitive diagnosis of MTP deficiency in a patient when insufficient biopsy material 
was available for the analysis of the MTP protein or RNA. Second, the functional 
studies of the substitution of Leu435 to a charged amino acid (acid Glu or basic His) 
highlight the requirement for this hydrophobic un-charged residue for MTP activity. 
Third, in cases of unusual phenotype, the functional characterization of the MTTP 
mutants allows a better understanding of the milder ABL phenotype. 
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Figure 1: Ultrastructure of intestinal and liver biopsies after a 12-hour fast.  
 
Figure 2: Triglyceride transfer activity of normal and mutant MTTP in COS-1 cells over a period 
of 48h.  
 
Figure 3: Size separation of RT-PCR products as determined by 2% agarose gel 
electrophoresis:  
 
Figure 4: Intestinal biosynthesis of ApoB48 and MTP in organ culture 
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Table 1: Biological data for the patient and the parents. 
 
TC 
mmol/L 
TG 
mmol/L 
HDLC 
mmol/L 
LDLC 
mmol/L 
ApoB 
g/L 
ApoA1 
g/L 
VitE 
µmol/L 
VitA 
µmol/L 
VitD 
nmol/L 
ALT 
UI/L 
AST 
UI/L 
ALB 
g/L 
BMI 
kg/m2 
Reference interval* 2.58-4.39 0.34-1.25 >1.03 1.81-3.10 0.5-1.2 1.1-2.0 11-35 1.4-3.0 34-130 <30 <30 35-50  
Patient  
(at diagnosis, 4yrs of 
age) 
1.68 0.58 0.85 0.57 < 0.18 ND 9.9 1.7 159 287 272 32 14 
Oral fat load (5yrs) 
T0 
2.27 1.15 2.17  0.20 0.93        
Oral fat load 
T 90 min 
2.06 1.50 1.86  0.20 0.99        
Patient  
(22yrs old) 
(reduced fat diet) 
2.24 0.64 1.70 0.26 ND ND 18.9 3 96 49 41 45 17.8 
Father 5.42 0.97 1.42 3.57          
Mother 4.64 1.84 1.52 2.77 1.01 1.19    18 14   
 
TC total cholesterol, TG triglyceride, HDLC HDL cholesterol, LDLC LDL cholesterol, Vit vitamin, ALT Alanine aminotransferase, AST Aspartate 
aminotransferase, ALB albumin, BMI body mass index, ND : not determined 
* normal values for 4 a year old child. 
Oral fat load with 15g of fat.  
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Table 2: Atypical mild cases of ABL reported in the literature 
 
case 1 case 2 case 3 case 4 case 5 
ref. (42) (13) (19) (15) (14) 
mutation 
[c. 61+2T>C]+ 
[c.419-420insA] 
homozygous 
p.Asn780Tyr 
[c. 61+1G>C]+ 
[p.Ile564Thr] 
homozygous 
p.Ser590Ile 
homozygous 
p.Ser590Ile 
age at diagnosis 
(year) 
13 27 1.25 52 24 
age at present 
(year) 
32 27 5 52 44 
context of 
diagnosis 
NA 
during a routine 
medical 
examination 
hepatomegaly + 
liver dysfunction 
during a routine 
medical 
examination 
NA 
malabsorption + 0 NA + + 
liver 
impairements 
ALT, AST, GGT 
increased 
mild fatty liver 
hepatomegaly, 
steatosis, fibrosis 
NA NA 
neurological 
impairements 
reduced reflexes 0 0 0 0 
ophtalmological 
impairements 
minor 
xerophtalmia, 
abnormal dryness 
of membrane of 
the eyes 
0 0 
atypical retinitis 
pigmentosa 
retinopathy 
Vit E (µmol/L) 
14 (RI: 12-36) on 
replacement 
therapy 
<2.4 10 (RI: 18-34) 23 (RI: 12-46) NA 
TC (mmol/L) 0.90 0.87 1.25 to 2.36 0.85 NA 
TG (mmol/L) 0.50 0.03 0.11 to 1.14 0.06 NA 
HDLC (mmol/L) 0.50 0.59 NA 0.68 0.56 
LDLC (mmol/L) 0.07 NA NA 0.16 NA 
ApoB (g/L) 0.06 0.006 < 0.007 NA NA 
MTTP activity NA negligible NA NA NA 
 
TC total cholesterol, TG triglyceride, HDLC HDL cholesterol, LDLC LDL cholesterol, Vit + present, 0 absent, NA not 
available, RI reference interval 
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The enterocytes (a,b) and hepatocytes (c) were 
engorged with numerous small or very large lipid 
droplets (L) free in the cytoplasm. The Golgi apparatus 
(G) is empty (b). Hepatic intercellular spaces were 
sometimes enlarged with fibrosis (c). The cell nucleus 
is labelled N.  
Figure 1 
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Figure 2 
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Cell homogenates were used to measure triglyceride 
transfer from donor to acceptor vesicles using 
fluorescent-labelled method membranes. Columns and 
bars represents means +/- SD (n=2). 
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Figure 3 
M: molecular weight marker, lanes 1, 2, 3: normal 
minigene, lane 4 5 6: mutant (c.619-5_619-2del) 
minigene. 
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ApoB48 was synthesized by the duodenal biopsy (B) 
and secreted in the medium (M) with the same 
molecular weight as normal control (N). MTP from the 
patient had the same molecular weight as normal 
control (N). PDI was coimmunoprecipitated: the 
binding of MTP with PDI was intact in the intestinal 
biopsy. 
Figure 4 
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Supplemental Data 1 : Sequencing of genomic DNA
Figure 1A : Sequencing of the exon 10 of the MTTP gene
Figure 1B : Sequencing of the intron 5 and exon 6 of the MTTP gene
M    1      2      3      4     5    6 M    1     2    3     4    5    6 
5 µL of RT-PCR products were loaded on a 2% agarose gel. A: Total RNA was extracted
from COS-1 cells transfected with the wild type MTP c.DNA (1) or the p.Leu435His c.DNA
(2) or the p.Leu435Val c.DNA (3) or the p.Leu435Glu c.DNA (4) or the p.Cys194Stop 
c.DNA (5) or untransfected (6). After reverse transcription, amplification of a 706 bp
fragment was performed with primers cMTTP-946F and cMTTP-1098rev. B: same as A 
but a 1582 bp PDI c.DNA fragment was amplified with primers PDI-Hind3-1 and PDI-
Hind3-2. 
A B
Supplemental Data Figure 2
C
COS-1 cells were transfected with MTTP-AcGFP1 fusion vector by microporation. 
Fluorescence was observed using Nikon Eclipse TE 2000-U microscope (objective 20) 48 
hours after transfection.
Wild type p. Leu435His
GFP alone Untransfected
COS-1 cells
p.Cys194Stop
Sequencing of the 248 bp RT- PCR product from minigene transfection : 
pTB exon 3 Beginning of MTTP exon 7
End of MTTP exon 7 pTB exon 4
Sequencing of the 386 bp RT- PCR product from minigene transfection : 
pTB exon 3 pTB exon 4
Supplemental Data Figure 3
